Vaccination News

In this episode, host Shikha Jain, MD, speaks with Michael Roizen, MD, author and chief wellness officer at the Cleveland Clinic, about developing tools that can help lead to a longer life, public health messaging in media and more.

A single dose of the Jynneos mpox vaccine reduces hospitalization risk and disease severity, a study found, although researchers emphasized that people at risk for the disease should complete the two-dose vaccine series.

Researchers investigating the value of asymptomatic SARS-CoV-2 testing in a hospital setting reported that it provided clinically relevant data, and it may be more “clinically meaningful” to conduct among those who are not fully vaccinated.

Updated COVID-19 shots, including bivalent boosters, dominated vaccine news in 2022, but good news also came for vaccines against malaria, Ebola and cancer.

People who were more physically active prior to developing COVID-19 had a lower risk for severe outcomes than those who were less physically active, according to researchers.

Mpox spread around the globe in 2022, popping up in 110 countries — including 103 that had not historically reported the disease, according to CDC tracking.

An asymptomatic SARS-CoV-2 patient admission testing program can provide clinically relevant data, even during periods of lower transmission in which testing can be limited to patients who are not fully vaccinated, a recent study showed.

Over the past year, Healio has covered new discoveries about the COVID-19 vaccine, including evidence of its efficacy, the impact of vaccination during pregnancy, uptake disparities and more.

During the 2021-2022 influenza season, vaccination significantly reduced outpatient visits, consistent with prior seasons during which A(H3N2) viruses were predominant, especially among younger patients, recent study data showed.

In an exclusive interview conducted during his final days in office, Anthony S. Fauci, MD, reflected on his time with the National Institute of Allergy and Infectious Diseases and what is next for him and the field of infectious disease.